Esperion Therapeutics Inc. (ESPR) Volatility Spurs A Quest For Clarity

Currently, there are 170.42M common shares owned by the public and among those 168.54M shares have been available to trade.

The company’s stock has a 5-day price change of 21.83% and -9.42% over the past three months. ESPR shares are trading -6.69% year to date (YTD), with the 12-month market performance up to 56.74% higher. It has a 12-month low price of $0.70 and touched a high of $3.34 over the same period. ESPR has an average intraday trading volume of 6.42 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 20.94%, 17.81%, and 64.62% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Esperion Therapeutics Inc. (NASDAQ: ESPR) shares accounts for 48.10% of the company’s 170.42M shares outstanding.

It has a market capitalization of $475.47M and a beta (3y monthly) value of 0.83. The earnings-per-share (ttm) stands at -$2.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.24% over the week and 9.77% over the month.

Analysts forecast that Esperion Therapeutics Inc. (ESPR) will achieve an EPS of $0.05 for the current quarter, -$0.21 for the next quarter and $0.05 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.31 while analysts give the company a high EPS estimate of $0.46. Comparatively, EPS for the current quarter was -$0.79 a year ago. Earnings per share for the fiscal year are expected to increase by 80.93%, and 113.47% over the next financial year. EPS should shrink at an annualized rate of 16.90% over the next five years, compared to 23.09% over the past 5-year period.

Northland Capital was of a view on August 01, 2023 that the stock is Market Perform, while BofA Securities gave the stock Buy rating on June 15, 2023, issuing a price target of $1.25- $4. Northland Capital on their part issued Under Perform rating on March 16, 2023.

Most Popular

Related Posts